Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Enzo Biochem, Inc. (ENZ : NYSE)
 
 • Company Description   
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.

Number of Employees: 514

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.40 Daily Weekly Monthly
20 Day Moving Average: 65,971 shares
Shares Outstanding: 48.71 (millions)
Market Capitalization: $116.90 (millions)
Beta: 0.80
52 Week High: $4.15
52 Week Low: $2.23
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -16.38% -5.81%
12 Week -27.71% -20.52%
Year To Date -25.23% -8.65%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
527 Madison Ave.
-
New York,NY 10022
USA
ph: 212-583-0100
fax: 212-679-7999
ir@enzo.com http://www.enzo.com
 
 • General Corporate Information   
Officers
Elazar Rabbani - Chief Executive Officer;Chairman of Board of Direc
Barry W. Weiner - President and Treasurer
David Bench - Chief Financial Officer; Principal Accounting Of
Dov Perlysky - Director
Mary Tagliaferri - Director

Peer Information
Enzo Biochem, Inc. (CORR.)
Enzo Biochem, Inc. (RSPI)
Enzo Biochem, Inc. (CGXP)
Enzo Biochem, Inc. (BGEN)
Enzo Biochem, Inc. (GTBP)
Enzo Biochem, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 294100102
SIC: 8071
Fiscal Year
Fiscal Year End: July
Last Reported Quarter: 01/01/22
Next Expected EPS Date: 06/08/22
Share - Related Items
Shares Outstanding: 48.71
Most Recent Split Date: 10.00 (1.05:1)
Beta: 0.80
Market Capitalization: $116.90 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 06/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: 24.00
PEG Ratio: -
Price Ratios
Price/Book: 1.79
Price/Cash Flow: 9.19
Price / Sales: 0.99
EPS Growth
vs. Year Ago Period: -66.67%
vs. Previous Quarter: 175.00%
Sales Growth
vs. Year Ago Period: 8.20%
vs. Previous Quarter: 28.38%
ROE
04/30/22 - -
01/31/22 - 7.42
10/31/21 - 11.85
ROA
04/30/22 - -
01/31/22 - 4.43
10/31/21 - 6.94
Current Ratio
04/30/22 - -
01/31/22 - 2.55
10/31/21 - 2.85
Quick Ratio
04/30/22 - -
01/31/22 - 2.02
10/31/21 - 2.25
Operating Margin
04/30/22 - -
01/31/22 - 4.17
10/31/21 - 6.72
Net Margin
04/30/22 - -
01/31/22 - 0.25
10/31/21 - 4.55
Pre-Tax Margin
04/30/22 - -
01/31/22 - 0.25
10/31/21 - 4.55
Book Value
04/30/22 - -
01/31/22 - 1.34
10/31/21 - 1.38
Inventory Turnover
04/30/22 - -
01/31/22 - 5.04
10/31/21 - 5.35
Debt-to-Equity
04/30/22 - -
01/31/22 - 0.07
10/31/21 - 0.06
Debt-to-Capital
04/30/22 - -
01/31/22 - 6.26
10/31/21 - 6.07
 

Powered by Zacks Investment Research ©